AVEZ-VOUS DES QUESTIONS? CLIQUEZ ICI
Nantes, France, 18 Mars 2020
Cher Partenaire,
Dans ce contexte inédit de lutte contre la propagation du virus Covid-19, Biomatlante s’est adaptée pour assurer la continuité de ses services afin de vous accompagner et vous soutenir dans votre activité.
Félicitations de la part de l’équipe !
Biomatlante is very pleased to announce the acquisition of 100% of its shares by Advanced Medical Solutions Group plc (London Alternative Investment Market: AMS).
Just after BSI last January, TÜV Süd Product Service GmbH is now the second Notified Body designated to issue CE Marking certifications under the European Medical Devices Regulation (MDR).
Biomatlante, a world leader in synthetic bone regeneration technologies, is pleased to announce the obtention of the MDSAP* accreditation on the new ISO 13485:2016 Certificate.
Julien Dert nommé nouveau directeur général de Biomatlante, Chantal Gobin conserve la présidence du conseil d'administration
Biomatlante, acteur mondial des technologies de régénération osseuse synthétique, a le plaisir d'annoncer la nomination de son nouveau DG, Julien Dert, à compter de ce 1er février 2019.
The article shows the valorization of results of a non interventional clinical study of 78 patients with the product In’Oss™ in association with a collagen resorbable membrane in maxillofacial surgery. The safety and efficacy of In’Oss has been demonstrated, as well as the performance of EZ Cure membrane associated to it.
Six commercially available CaP bone substitutes (Bio-Oss, Actifuse, Bi-Ostetic, MBCP, Vitoss and chronOs) as well as two tricalcium phosphate (TCP) ceramics with either a micron-scale (TCP-B) or submicronscale (TCP-S) surface structure are characterized and their bone forming potential is evaluated in a canine ectopic implantation model.
After the success of the European program REBORNE (FP7) focused on safety and efficacy of the Biomatlante matrix combined with autologous bone marrow expanded mesenchymal stem cells (MSC), MBCP+™, made from our well-known MBCP Technology, was confirmed as the adapted matrix for tissue engineering and chosen for 2 new European research programs (H2020): MAXIBONE and ORTHOUNION.
Coordinated by INSERM (Institut National de la Santé et de la Recherche Médicale) and with the support of the E.U., the REBORNE Program sought to establish the feasibility, relevance and efficacy of the association of MBCP+™*, a synthetic bone graft manufactured by Biomatlante made from MBCP™ Technology, and Mesenchymal Stem Cells (MSCs)1.
Introduction: Bone is the most transplanted tissue in human with about 1 million procedures annually in Europe. Autologous bone grafting is the gold standard in bone regeneration but it requires a second surgery, is limited in quantity and often associated with painful complications. Synthetic calcium phosphate biomaterial in association with mesenchymal stem cells may be a potent alternative to autologous bone grafting.
Emmanuel Macron, minister of Economy, met May 18, 2015 in Nantes, with the actors mobilized for the reindustrialization project “the Industry of the Future”, new array of industrial strategy. On its way to play a mainly role in the phase II of New Industrial France (NFI), this project aims to modernize the industrial tool and transform its business model by digital.
Prochains Evènements
-
ESSKA
(May 11, 2021 ) -
AAOS
(September 01, 2021 ) -
NASS - 2021
(September 29, 2021 ) -
EUROSPINE
(October 13, 2021 )
Evènements passés
Biomatlante a été à l'avant-garde du développement d'une nouvelle greffe osseuse synthétique.
5 Rue Edouard Belin, 44360 Vigneux-de-Bretagne, France
+33 2 28 02 00 09
Contact@biomatlante.com
5 Rue Edouard Belin, 44360 Vigneux-de-Bretagne, France
+33 2 28 02 00 09
Contact@biomatlante.com